Dr. Itay D. Melamed, MD

Dr. Melamed practices at CHI Alegent Health Physical Therapy Clinic Bergan - Unit in Omaha, Nebraska.

Dr. Melamed's NPI, 1619078656, was assigned on September 25, 2006. Dr. Melamed holds Pennsylvania license MD458897.

Dr. Melamed's primary practice is CHI Alegent Health Physical Therapy Clinic Bergan - Unit, at 7710 Mercy Rd, Omaha, NE 68124.

Dr. Melamed's primary practice is CHI Alegent Health Physical Therapy Clinic Bergan - Unit in Omaha, Nebraska. Dr. Melamed is also affiliated with CHI Health Creighton University Medical Center - Bergan Mercy. The medical group on file is CHI Health Clinic. Dmand AI also links Dr. Melamed to 2 more hospitals, 4 medical groups, 2 group practices and clinics and 1 hospital outpatient department, each named with a free account. Dr. Melamed's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melamed practices, 7 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Melamed's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dmand AI has Dr. Melamed's licenses on file in 3 states: Pennsylvania, Colorado and Missouri.

CMS data shows 19 Medicare services from Dr. Melamed across 1 procedure code in 2024, all of them office visits, for 63 Medicare patients. Medicare paid $1,480 for them. Every service was in an office.

CMS counts 63 Medicare patients who saw Dr. Melamed in 2024. The largest group is 75 to 84, with 26 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Melamed's median patient age at 67, with 58% women.

In 2023, Dr. Melamed wrote 32 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $267 in total drug cost. In 2022, CMS named 16 claims across 1 drug.

Dr. Melamed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melamed as offering telehealth.

Dmand AI links 7 papers to Dr. Melamed, published from 2021 to 2022. 2022 was the busiest year, with 4. The most frequent topics are Brain Ischemia, Ischemic Stroke and Stroke. Dr. Melamed's most frequent co-authors are Clemens M. Schirmer, MD, Oded Goren, MD and Christoph Johannes Griessenauer, MD.

Dmand AI links Dr. Melamed to 2 clinical trials. Conditions studied include Brain Ischemia, Headache and Migraine Disorders. Open Payments lists research payments to Dr. Melamed that name 1 trial.

CMS Open Payments shows 20 general payments to Dr. Melamed from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Medtronic, Inc. paid the most, $209. It also lists 2 research payments totaling $10,302 from 2017 to 2018, naming 1 clinical trial.